Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial looking at lenalidomide (Revlimid) for B cell chronic lymphocytic leukaemia that has responded to second line chemotherapy (The CONTINUUM Trial)
This trial compared lenalidomide with a dummy drug (placebo) to see if it stopped chronic lymphocytic leukaemia coming back after second line chemotherapy. It was for people with B cell chronic lymphocytic leukaemia that had responded to 2nd line treatment.
This trial started in 2009 and the results were published in 2017.
More about this trial
Treatment for chronic lymphocytic leukaemia (CLL) is usually chemotherapy. When the first treatment stops working, your doctor may suggest you have another type. This is called second line treatment.
Lenalidomide is a type of targeted cancer drug. It works mainly by helping the body’s
The aim of this trial was to find out if lenalidomide stopped B cell CLL coming back after responding to second line chemotherapy.
Summary of results
- 160 people had lenalidomide
- 154 people had a dummy drug (
- just under 3 years for those who had lenalidomide
- just over 9 months for those who had the dummy drug
- a drop in blood cells
The trial team concluded that lenalidomide can help stop B cell CLL coming back after 2nd line treatment. And that lenalidomide wouldn’t affect how well any future treatment would work.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Prof Andrew Pettitt
ICON Clinical Research (UK) Limited